ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, develops therapeutics for the treatment cancer in Asia, the United States, Europe, and internationally. The company's product pipeline includes Varlitinib, a novel agent, which has completed Phase II studies in gastric and breast cancer, and entered into pivotal studies for biliary tract cancer; ASLAN002, a potent cMET and Recepteur d'Origine Nantais (RON) inhibitor that is in Phase II development for the treatment of gastric and breast cancer; and ASLAN003, a novel DHODH inhibitor, which is in Phase I clinical trials to treat acute myeloid leukemia and solid tumors. It is also developing ASLAN004, a monoclonal IL4/IL13 antibody that is under preclinical development for asthma and other tumor types; and ASLAN005, a monoclonal antibody, which is under preclinical development for RON, an immune checkpoint inhibitor. In addition, the company is also discovering Modybodies that are a novel type of antibody fragments, which can be linked together into heterodimers/trimers to inhibit various targets. ASLAN Pharmaceuticals Limited was founded in 2014 and is headquartered in Singapore.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASLN
Previous Symbol
CUSIPN/A
Phone65-6222-4235
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees47
Outstanding Shares32,030,000
Market Cap$164.93 million
OptionableNot Optionable
ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) Frequently Asked Questions
What is ASLAN PHARMACEUTICALS ADR REP 5's stock symbol?
ASLAN PHARMACEUTICALS ADR REP 5 trades on the NASDAQ under the ticker symbol "ASLN."
What price target have analysts set for ASLN?
4 brokers have issued 12 month price targets for ASLAN PHARMACEUTICALS ADR REP 5's stock. Their predictions range from $7.00 to $16.00. On average, they anticipate ASLAN PHARMACEUTICALS ADR REP 5's stock price to reach $11.6667 in the next twelve months. This suggests a possible upside of 128.8% from the stock's current price. View Analyst Price Targets for ASLAN PHARMACEUTICALS ADR REP 5.
What is the consensus analysts' recommendation for ASLAN PHARMACEUTICALS ADR REP 5?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN PHARMACEUTICALS ADR REP 5 in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ASLAN PHARMACEUTICALS ADR REP 5.
What are Wall Street analysts saying about ASLAN PHARMACEUTICALS ADR REP 5 stock?
Here are some recent quotes from research analysts about ASLAN PHARMACEUTICALS ADR REP 5 stock:
- 1. According to Zacks Investment Research, "ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company's product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003 both are in clinical stage. ASLAN Pharmaceuticals Limited is based in Singapore. " (11/9/2018)
- 2. HC Wainwright analysts commented, "We have valuated ASLAN using a DCF-based methodology, which yields a risk-adjusted enterprise value of $394M for varlitinib and ASLAN003, using a 15% discount rate and 0.5% terminal growth rate. Our probabilities of success are 65% for varlitinib in BTC, 30% for varlitinib in in AML. Investment risks include: (1) failure of varlitinib or ASLAN003 in clinical trials; (2) failure varlitinib or ASLAN003 to secure regulatory approval; (3) failure of varlitinib or ASLAN003 to achieve commercial success due to market size, penetration rate, or competition; and (4) potential dilution risk." (8/21/2018)
Has ASLAN PHARMACEUTICALS ADR REP 5 been receiving favorable news coverage?
Media stories about ASLN stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. ASLAN PHARMACEUTICALS ADR REP 5 earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of ASLAN PHARMACEUTICALS ADR REP 5's key competitors?
Some companies that are related to ASLAN PHARMACEUTICALS ADR REP 5 include Inflarx (IFRX), CytomX Therapeutics (CTMX), Urogen Pharma (URGN), Vectura Group (VEGPF), AC Immune (ACIU), Flexion Therapeutics (FLXN), Assembly Biosciences (ASMB), ANI Pharmaceuticals (ANIP), Epizyme (EPZM), AMAG Pharmaceuticals (AMAG), Omeros (OMER), NuCana (NCNA), Principia Biopharma (PRNB), Collegium Pharmaceutical (COLL) and CymaBay Therapeutics (CBAY).
Who are ASLAN PHARMACEUTICALS ADR REP 5's key executives?
ASLAN PHARMACEUTICALS ADR REP 5's management team includes the folowing people:
- Dr. Carl Alan Jason Morton Firth, Chairman & CEO (Age 45)
- Mr. Kiran Asarpota, VP of Fin.
- Dr. Mark McHale, Chief Operating Officer
- Charlie Hsu, Investor Relations Director
- Mr. Ben Goodger, Gen. Counsel
When did ASLAN PHARMACEUTICALS ADR REP 5 IPO?
(ASLN) raised $60 million in an initial public offering (IPO) on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.
When did the company's lock-up period expire?
ASLAN PHARMACEUTICALS ADR REP 5's lock-up period expired on Wednesday, October 31st. ASLAN PHARMACEUTICALS ADR REP 5 had issued 6,000,000 shares in its initial public offering on May 4th. The total size of the offering was $42,180,000 based on an initial share price of $7.03. Since the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
How do I buy shares of ASLAN PHARMACEUTICALS ADR REP 5?
Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ASLAN PHARMACEUTICALS ADR REP 5's stock price today?
One share of ASLN stock can currently be purchased for approximately $5.10.
How big of a company is ASLAN PHARMACEUTICALS ADR REP 5?
ASLAN PHARMACEUTICALS ADR REP 5 has a market capitalization of $164.93 million. ASLAN PHARMACEUTICALS ADR REP 5 employs 47 workers across the globe.
What is ASLAN PHARMACEUTICALS ADR REP 5's official website?
How can I contact ASLAN PHARMACEUTICALS ADR REP 5?
ASLAN PHARMACEUTICALS ADR REP 5's mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at 65-6222-4235 or via email at [email protected]
MarketBeat Community Rating for ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ ASLN)
MarketBeat's community ratings are surveys of what our community members think about ASLAN PHARMACEUTICALS ADR REP 5 and other stocks. Vote "Outperform" if you believe ASLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
